Description
Silvitra
Silvitra is a product name used for a tablet described as containing sildenafil plus vardenafil. Both are phosphodiesterase type 5 (PDE5) inhibitors used in the treatment of erectile dysfunction. However, this specific fixed-dose combination is not a standard authorised medicine in the regulatory sources reviewed, so the information below is based on the verified properties of the two active ingredients rather than on a confirmed approved combination product.
Active Ingredient and Medicine Class
Sildenafil and vardenafil are oral PDE5 inhibitors. This drug class increases blood flow in erectile tissue by enhancing the nitric oxide–cGMP pathway. Sildenafil is the active substance in Viagra and related products, while vardenafil is the active substance in Levitra and related products.
Established Medical Uses
Both sildenafil and vardenafil are established treatments for erectile dysfunction in adult men. Regulatory product information for each agent identifies this as the approved therapeutic use. The literature also supports efficacy across multiple patient groups, including men with diabetes and other common causes of erectile dysfunction.
How It Works
During sexual stimulation, nitric oxide triggers production of cGMP in penile tissue, which relaxes smooth muscle and allows increased blood flow. Sildenafil and vardenafil inhibit PDE5, the enzyme that breaks down cGMP, helping maintain the erectile response.
Important Safety Information
PDE5 inhibitors are contraindicated with nitrates and nitric oxide donors because of the risk of marked blood-pressure lowering. Vardenafil is also not recommended in certain patients with significant cardiovascular instability, including recent myocardial infarction or stroke, severe heart failure, uncontrolled hypertension, or hypotension. Caution is also needed with alpha-blockers and with strong CYP3A4 inhibitors, which can increase exposure and adverse effects. Concomitant use with other erectile dysfunction therapies is not recommended.
Possible Side Effects
Common adverse effects of this drug class include headache, flushing, nasal congestion, dyspepsia, and dizziness. Important serious reactions can include priapism, sudden hearing or vision problems, symptomatic hypotension, and cardiovascular events in susceptible patients. Vardenafil trials and reviews report generally dose-related adverse effects.
Scientific Evidence
PubMed-indexed reviews and meta-analyses show that sildenafil and vardenafil improve erectile function versus placebo, and that vardenafil has demonstrated clinically meaningful benefits in randomised trials. Comparative evidence suggests that both medicines are effective, while differences in efficacy and adverse-event patterns may vary across studies and doses. There is no strong clinical evidence establishing any advantage for combining sildenafil with vardenafil in one product.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, product-specific prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration (FDA) — LEVITRA (vardenafil hydrochloride) tablets, for oral use
- U.S. Food and Drug Administration (FDA) — LEVITRA (vardenafil hydrochloride) tablets, for oral use
- Gillian M. Keating et al. — Vardenafil: a review of its use in erectile dysfunction — Drugs (2003)
